Frexalimab

Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research[1][2][3][4][5].

Product Specifications

CAS Number

[2515463-86-0]

Product Name Alternative

SAR441344; INX-021

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/frexalimab.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[Frexalimab]

Molecular Weight

(145.698 kDa)

References & Citations

[1]Bruce A C Cree, et al. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022 Jun 1;35 (3) :262-270. |[2]Vermersch P, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. N Engl J Med. 2024 Feb 15;390 (7) :589-600. |[3]Carvalho T. Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis. Nat Med. 2023 Aug;29 (8) :1882-1883. |[4]Weiskorn J, et al. Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes. Horm Res Paediatr. 2024 Apr 30:1-8. |[5]Maddaloni E, et al. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2024 Apr;33 (4) :303-318.